Epogen :: Science Biology Papers

EpogenEpogen is produced by the company Amgen. Amgen find at thou Oaks, California, is a global biotechnology company. It discovers, develops, manufactures, and markets human therapeutics based on travel cellular and molecular biology. Amgen, founded in 1980, is now the largest biotechnology company in the world. It has 4,200 employers around the world and 2,700 of the 4,200 workers, work at the headquarters in Thousand Oaks. Amgen has centers of research in Boulder, Colorado and Toronto, Canada clinical research centers in Cambridge, England and Melbourne, Australia the supranational distribution center in Louisville, Kentucky, fill and finish facility in Junco, Puerto Rico and European regional headquarters in Lucerne, Switzerland. Amgen has other transnational offices that are located in Austria, Australin, Belgium, Canada, China, France, Germany, Italy, Japan, the Netherlands, Hong Kong, Portugal, Spain, and the United Kingdom. (Amgen 1996)Amgens first product, Epogen was app roved in June 1989 for use of goods and services in the United States. Neupogen (filgrastim) Amgens due south product, received approval for use in February 1991, is used for preventing infections in cancer patients that receive chemotherapy for bone content and peripheral blood progenitor cell transplantation patients and treatment for inveterate neutropenia, which is a rare blood disorder. Amgen has research in the areas of hematopoiesis, neurobiology, inflammation/autoimmunity, and bonkers tissue repair and regeneration. Products from the research, in the four areas mentioned from above, may, sometime in the future, be used in treating conditions characterized by disorders of blood and bone marrow, neurodegenerative diseases such as ALS, Parkinsons, Alzheimers, or traumatic nerve injury.EpogenEpoetin Alfa recombinant Epogen, or Epogen, has 3,000 units of recombinant Epoetin Alfa, 2.5 mg Albumin (Human) in sterile buffe reddened solution (pH 6.9 +/- 0.3) of sodium citrate (5.8 mg), sodium chloride (5.8mg), citric acidulous (0.06mg), in Water for injection.Its uses are stimulating the body to make red blood cells, treatments of anemia (loss or reduction of red blood cells) associated with degenerative renal failure or anemia caused by AZT (zidovudine) in HIV-infected persons. Before Epogen was produced or used, blood transfusions and male hormone therapy was used in treating anemia, which was caused by chronic renal failure. Epogen StudiesStudies on Epogen are available from Amgen, intellectual nourishment and Drug Administration (FDA), and the Journal of the American Society of Nephrology. One vignette by Amgen was to establish the safety and efficacy of EPOGEN in pediatric patients (Amgen 89), the second study from FDA, was about erythropoietin, which is